Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Zippelius

Showing results (91-100 of 163) with videos related to

Pageof 17
Sort By:
Nature Communications|May 27, 2017
Replicating viral vector platform exploits alarmin signals for potent CD8<sup>+</sup> T cell-mediated tumour immunotherapySandra M Kallert, Stephanie Darbre, Weldy V Bonilla, et al.
BMC Cancer|October 8, 2014
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancerMartin Sebastian, Alexandros Papachristofilou, Christian Weiss, et al.
Nature Immunology|March 14, 2019
Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycleWan-Chen Cheng, Yao-Chen Tsui, Simone Ragusa, et al.
Cancer Research|April 17, 2004
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional toleranceAlfred Zippelius, Pascal Batard, Verena Rubio-Godoy, et al.
Nature Immunology|January 22, 2019
Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycleWan-Chen Cheng, Yao-Chen Tsui, Simone Ragusa, et al.
Immunity|September 29, 2022
High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificityRodrigo Vazquez-Lombardi, Johanna S Jung, Fabrice S Schlatter, et al.
Medrxiv : the Preprint Server for Health Sciences|November 19, 2025
A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinomaSilvia Guglietta, Anne Bärenwaldt, Anthony Sonrel, et al.
Cancer Immunology Research|June 12, 2014
Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cellsPhilipp Müller, Kea Martin, Sebastian Theurich, et al.
Breast Cancer Research : BCR|November 22, 2018
Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancerMarcus Vetter, Julia Landin, Barbara Maria Szczerba, et al.
Cancer Immunity|May 20, 2004
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFADanielle Liénard, Donata Rimoldi, Marie Marchand, et al.
Pageof 17

Showing results (91-100 of 163) with videos related to

Sort By:
Pageof 17
Nature Communications|May 27, 2017
Replicating viral vector platform exploits alarmin signals for potent CD8<sup>+</sup> T cell-mediated tumour immunotherapySandra M Kallert, Stephanie Darbre, Weldy V Bonilla, et al.
BMC Cancer|October 8, 2014
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancerMartin Sebastian, Alexandros Papachristofilou, Christian Weiss, et al.
Nature Immunology|March 14, 2019
Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycleWan-Chen Cheng, Yao-Chen Tsui, Simone Ragusa, et al.
Cancer Research|April 17, 2004
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional toleranceAlfred Zippelius, Pascal Batard, Verena Rubio-Godoy, et al.
Nature Immunology|January 22, 2019
Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycleWan-Chen Cheng, Yao-Chen Tsui, Simone Ragusa, et al.
Immunity|September 29, 2022
High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificityRodrigo Vazquez-Lombardi, Johanna S Jung, Fabrice S Schlatter, et al.
Medrxiv : the Preprint Server for Health Sciences|November 19, 2025
A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinomaSilvia Guglietta, Anne Bärenwaldt, Anthony Sonrel, et al.
Cancer Immunology Research|June 12, 2014
Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cellsPhilipp Müller, Kea Martin, Sebastian Theurich, et al.
Breast Cancer Research : BCR|November 22, 2018
Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancerMarcus Vetter, Julia Landin, Barbara Maria Szczerba, et al.
Cancer Immunity|May 20, 2004
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFADanielle Liénard, Donata Rimoldi, Marie Marchand, et al.
Pageof 17